2024年10月3日 · Current Market: As of 2024, the FDA has approved 13 ADCs, including Trodelvy® (sacituzumab govitecan-hziy). Initially approved for triple-negative metastatic breast …

2019年10月30日 · To date, a total of 13 ADCs have been approved by the FDA, including: ado-trastuzumab emtansine (Kadcyla™), brentuximab vedotin (Adcetris™), inotuzumab …

As of 2024, the U.S. Food and Drug Administration (FDA) has approved a number of ADCs for the treatment of a variety of malignancies such as breast cancer, non-small cell lung cancer, and …

2021年8月12日 · Approved ADC Drugs. Up to 2022, there are 17 ADC drugs on the market worldwide (table 1). After the withdrawal of the first drug Mylotarg, the ADC drug market did …

As of June 2023, eleven ADCs have been approved by the Food and Drug Administration (FDA) and are on the market. These drugs have been added to the therapeutic armamentarium of …

Antibody drug conjugates (ADCs) combine the dual advantages of small molecule and antibody drugs compared to antibody or small molecule drugs alone. Many ADCs have demonstrated …

In 2024 or 2025, three ADCs are expected to receive FDA approval: Datopotamab Deruxtecan (Dato-DXd), patritumab deruxtecan (HER3-DXd), and Telisotuzumab vedotin (ABBV-399).

Need detailed data for all approved antibodies, including those approved outside the US/EU? Access YAbS, an online database of antibody therapeutics. No login is needed to access data …

2024年3月23日 · Currently, there are 13 Food and Drug Administration (FDA)‒approved ADCs and more than 100 ADC drugs at different stages of clinical trials. This review briefly describes …

Antibody-drug conjugates have been shown to be more efficacious than traditional chemotherapy. To date, there are 13 ADCs approved by the United States Food and Drug Administration …